AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Alnylam Pharmaceuticals: JPMorgan Maintains Overweight, Raises PT to $348 from $338.
ByAinvest
Wednesday, Jul 16, 2025 8:34 am ET1min read
Alnylam Pharmaceuticals: JPMorgan Maintains Overweight, Raises PT to $348 from $338.
Title: Alnylam Pharmaceuticals: JPMorgan Maintains Overweight, Raises PT to $348 from $338On July 2, 2025, JPMorgan maintained its "Overweight" rating for Alnylam Pharmaceuticals (ALNY, Financial), while raising the price target (PT) from $338 to $348. This adjustment reflects a bullish sentiment from the investment bank, indicating confidence in the company's future performance.
JPMorgan's decision to raise the PT is based on several positive factors, including Alnylam's strong pipeline of RNA interference (RNAi) therapeutics and the recent success of its lead product, Amvuttra. The company's strategic direction and financial health have been consistently praised by analysts, with Citigroup recently raising its price target to $404, a significant increase of approximately 11% from its previous target of $364 [1].
The consensus among analysts is overwhelmingly positive, with 23 out of 28 analysts rating Alnylam as a "Strong Buy." The average price target for Alnylam is $330.48, with a high estimate of $500.00 and a low estimate of $212.00. This consensus indicates a potential upside of 4.52% from the current price of $316.19 [1].
GuruFocus estimates that Alnylam's GF Value in one year will be $440.59, suggesting a potential upside of 39.34% from the current price. The GF Value is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and future estimates of the business' performance [1].
In addition to the positive analyst ratings, Alnylam has shown strong technical indicators and strategic corporate actions, although the high financial leverage and negative earnings impact the valuation. The company's positive earnings call sentiment and corporate event developments highlight potential for future improvement [2].
Overall, JPMorgan's decision to maintain an "Overweight" rating and raise the price target reflects a positive outlook on Alnylam Pharmaceuticals' future prospects. Investors should closely monitor the company's progress and earnings reports to assess the potential for further upside.
References:
[1] https://www.gurufocus.com/news/2973008/alnylam-pharmaceuticals-alny-target-price-raised-by-citigroup-alny-stock-news
[2] https://www.tipranks.com/stocks/alny/forecast
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc's editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet